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Abstract  30	
Purpose of Review 31	
Methods that inform on dynamic metabolism that can be applied to clinical 32	
populations to understand disease progression and responses to therapeutic 33	
interventions are of great importance. This review perspective will highlight recent 34	
advances, development and applications of the multivalent stable isotope tracer D2O 35	
to the study of substrate metabolism with particular reference to protein, lipids and 36	
nucleic acids, and how these methods can be readily applied within clinical and 37	
pharmaceutical research. 38	
 39	
Recent Findings 40	
Advances in the application of D2O techniques now permit the simultaneous dynamic 41	
measurement of a range of substrates (i.e protein, lipid and nucleic acids, along with 42	
the potential for ‘OMIC’s methodologies) with minimal invasiveness- further creating 43	
opportunities for long-term ‘free living’ measures that can be used in clinical settings. 44	
These techniques have recently been applied to ageing populations and further in 45	
cancer patients revealing altered muscle protein metabolism. Additionally the efficacy 46	
of numerous drugs in improving lipoprotein profiles and controlling cellular 47	
proliferation in leukemia have been revealed. 48	
 49	
Summary 50	
D2O provides opportunities to create a more holistic picture of in vivo metabolic 51	
phenotypes, providing a unique platform for development in clinical applications and 52	
the emerging field of personalized medicine. 53	
 54	
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Introduction  57	
The ability to determine the metabolic regulation of diseases, ageing and trauma at 58	
the whole body or organ level has been a significant driver in scientific research. One 59	
of the major challenges to achieving this is how to capture the dynamic nature of 60	
metabolic processes in vivo, in humans. Stable isotopes are the research tool 61	
making this possible since they permit quantification of protein, lipid and nucleic acid 62	
metabolism, which has traditionally been performed through the use of substrate-63	
specific tracers (e.g. 13C/15N amino acid tracers, 13C palmitate, and 2H glucose) [1]. 64	
Recently, experimental use of the D2O tracer, which can be considered “non-65	
substrate specific” (i.e. incorporating into all major macromolecules), has undergone 66	
a resurgence (Figure 1) [2]. Here, we consider how D2O is revolutionising the study 67	
of in vivo dynamic metabolism; we describe the basis of D2O implementation, 68	
focusing on its use in humans and recent technical advances that extend the utility of 69	
this tracer to study human substrate metabolism in vivo, in particular its rapidly 70	
progressing translation to a clinical setting. 71	
 72	
Application of deuterium oxide as a stable isotope tracer 73	
D2O was one of the first isotope tracers to be used in metabolic research soon after 74	
it’s discovery by Harold Urey in 1932, the seminal works of Schoenheimer, 75	
Rittenberg and Ussing demonstrated incorporation of deuterium from D2O into many 76	
metabolic pools [1]. Once introduced into cellular pools D2O equilibrates throughout 77	
all body water and is incorporated into metabolites via condensation/hydrolysis 78	
reactions involving water; crucially, this occurs in a constant and predictable manner 79	
(Figure 1). Using appropriate D2O dosages, permits the  measurement of a huge 80	
range of metabolic processes, from the synthesis of deuterated precursors and their 81	
subsequent incorporation into polymers can be made e.g. deuterated alanine into 82	
protein, glucose into glycogen, fatty acids into triglycerides and ribose moieties into 83	
nucleic acids (RNA/DNA) (Table 1) [2]. D2O has a slow elimination rate from human 84	
Formatted: Superscript
Formatted: Superscript
Formatted: Superscript
Formatted: Subscript
Formatted: Subscript
Formatted: Subscript
Formatted: Subscript
Formatted: Subscript
Formatted: Subscript
Formatted: Subscript
Formatted: Subscript
body water (t½ 9-11 days) and so steady or pseudo-steady state enrichments can be 85	
easily maintained by regular daily or weekly top-ups, providing the unique potential 86	
for measurements of metabolism to be performed over hours, days, weeks or even 87	
months [3–6]. Further, by collection of regular saliva (or urine) samples, body water 88	
enrichment can be easily monitored throughout, tracking with precursor labeling, 89	
enabling subjects to undertake their usual habitual activity and dietary regimes. 90	
These unique properties of D2O has made the popularity of its application, 91	
particularly to human research, increase exponentially over recent years. A major 92	
advantage of using D2O over substrate-specific tracers is the ease of administration, 93	
being orally consumed negating the need for sterile I.V infusions and a controlled 94	
laboratory environment, such that subjects can be studied ‘free-living’ over long 95	
periods [3,6]. This provides a unique opportunity to metabolically phenotype a 96	
greater range of populations particularly in a clinical setting where access has been 97	
restricted or contraindicated with I.V tracers (i.e. in care homes, adolescents etc.).  98	
 99	
Recent progress in using D2O to study protein synthesis in humans 100	
Although the application of D2O to the measurement of protein turnover dates back to 101	
the work of Hans Ussing in 1941, it is only in the past decade that its validity for 102	
measuring muscle protein turnover has been established and subsequently applied 103	
in humans [3–7]. Given the importance of skeletal muscle as a metabolic tissue in 104	
health and disease, it is unsurprising the application of these techniques has initially 105	
been focused on the measurement of muscle protein synthesis (MPS). Moreover, the 106	
accessibility of skeletal muscle for biopsy coupled to the slow turnover of the body 107	
water pool makes D2O ideally suited for application to the study of this slowly turning 108	
over metabolic pool. One of the first attempts to measure the rate of MPS in humans 109	
maintained body water around 2% over a 6-week period (by ingesting 150 ml D2O 110	
(70 atom percent (AP)) per day during week 1 then 100 ml D2O daily thereafter). In 111	
comparing a young sedentary and an older group undertaking an aerobic training 112	
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program, the investigators showed greater MPS in the old group, demonstrating the 113	
utility of D2O for investigating the mechanisms of long-term “anabolic interventions” 114	
[2]. By further refining these principles with highly sensitive gas chromatography 115	
pyrolysis isotope ratio mass spectrometry (GC-pyr-IRMS), substantial improvements 116	
in the analytical limit of detection (LOD) and resolution were made, leading to the 117	
possibility of reduced D2O dosing i.e. a single bolus 150ml 70AP, permitting MPS 118	
measurement over 8 days [6]. This is especially important when one considers the 119	
potential issue of nausea associated with consumption of increased volumes of D2O. 120	
Using these refined techniques we proved the concept that exercise-induced 121	
increases in myofibrillar, collagen and sarcoplasmic fractional synthetic rates could 122	
be quantified over as little as 2 days, with measures of MPS over 3 hours (in 123	
response to amino acid feeding) also possible, simply by increasing the D2O dose 124	
[7]. Importantly, hourly MPS rates were identical to those we and others had shown 125	
in prior acute studies using stable-isotopically labeled AA  and in direct comparison 126	
with substrate-specific AA tracers, D2O yielded quantitatively similar increases in 127	
MPS with feeding [7].  128	
 129	
Following these initial measures of MPS with D2O, a series of studies have 130	
demonstrated its wide applicability for the study of both short-term (4-7 days) as well 131	
as longer-term (4-8 wks) interventions [3–6]. Predominantly, these so far have been 132	
used to demonstrate what has been coined “integrated” responses of MPS to a 133	
range of anabolic stimuli including; resistance exercise, high intensity interval training 134	
[8], aerobic exercise and long-term (4-wks) sprint interval training [9]. Further, we 135	
have demonstrated that there is significant hypertrophy and structural remodeling in 136	
the early stages of resistance exercise (~3-wks) supported by integrated increases in 137	
MPS [10,11]. Interestingly as training continued (up to 6-wks), increased MPS was 138	
attenuated despite progressive intensity [10], reflecting an adaptive waning to the 139	
anabolic stimulus. These studies have provided an integrated understanding of the 140	
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role of protein turnover in regulating established physiological adaptation to exercise 149	
[2]. 150	
 151	
D2O has also been recently used in a more clinical context. Advanced ageing is 152	
associated with a continual and progressive decline in skeletal muscle mass, quality 153	
and function [12]. While the etiology of this in humans remains poorly defined, it is 154	
clear that older individuals display blunted acute responses to anabolic stimuli such 155	
as feeding (particular amino acids and RE  – so called “anabolic resistance” [12,13]. 156	
Using D2O to compare long-term MPS between young and older individuals, we were 157	
the first to demonstrate that blunted acute responses of MPS to exercise also 158	
manifest as long-term deficits in MPS [10]. This was not necessarily predictable 159	
given the lack of linkage between acute MPS responses to exercise and resulting 160	
muscle hypertrophy. Moreover, recently, it was shown that studying nutrition as well 161	
as exercise interventions was also feasible; in this study, the authors showed that 162	
adding supplemental leucine to meals could increase integrated MPS in older 163	
individuals [4]. These studies demonstrate that D2O applications have the potential to 164	
inform on integrated and temporal responses to nutrition and exercise interventions 165	
in a “mechanistic fashion”. It is also of great interest that D2O has shown utility in a 166	
clinical setting in being applied to measure MPS in patients with upper GI cancer. 167	
Using a single bolus approach over 4 days immediately prior to surgery, patients 168	
losing weight had higher rates of MPS (0.073 %/h) when compared to weight stable 169	
and controls (0.058 %/h), possibly indicating greater protein turnover rates, although 170	
to lose muscle mass over time, protein breakdown would have to exceed MPS [14]. 171	
Nonetheless, this study does show the feasibility of applying D2O in clinical 172	
populations; future work will expand the use of this tracer and seek both mechanistic 173	
insight of disease/ageing processes in addition to nutritional, exercise or 174	
pharmacological interventions. Moreover, with the very recent introduction of 175	
dynamic proteomic techniques alongside the use of D2O, it is now possible to 176	
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measure the turnover of a large number of individual proteins [9] rather than studying 177	
bulk myofibrillar or collagen protein fractions, as outlined by the recent “Virtual 178	
Biopsy” technique [15]. These developments have opened up a whole new stream of 179	
measures to aid in the mechanistic understanding of human ageing and disease.  180	
 181	
Recent progress in using D2O to study fat and lipid metabolism 182	
 183	
Lipid metabolism has been the mainstay application of D2O for ~80 years. Great 184	
technical and methodological refinement over the past 70 years punctuated by the 185	
seminal works of Jungas, Previs and Brunengraber and Hellerstein and Parks have 186	
engendered an array of D2O based lipid assays [16]. For example, by measuring the 187	
amount of deuterium incorporated from water into newly synthesized fatty acids, 188	
glycerol-3-phosphate and/or cholesterol combined with mathematical modeling 189	
techniques, D2O has the unique potential for measuring rates of de novo lipogenesis 190	
(DNL), triglyceride synthesis (and turnover) and sterol biosynthesis simultaneously. 191	
The details, development and technical considerations for these techniques is 192	
beyond the scope of this review; the reader is directed to the following for more detail 193	
[1,2,16]. 194	
 195	
Much of the progress over the past 5-years has been in how these novel D2O based 196	
techniques can be applied (rather than further development of the isotopic theory of 197	
the models per se), particularly in terms of health, disease and the rapidly evolving 198	
discipline of personalized medicine. For example these techniques have helped to 199	
highlight the mechanisms underlying impaired adipose lipid metabolism in insulin 200	
resistant humans (e.g. highlighting decreased adipose DNL and TG synthesis: [17]), 201	
the mechanisms driving the increase in adiposity associated with chronic insulin 202	
treatment (through an increase in triglyceride synthesis or inhibition of lipolysis and 203	
the alterations to cholesterol flux due to dyslipidemia and coronary heart disease 204	
[18].However, more recently there has been marked progress in their implementation 205	
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alongside high throughput OMIC technologies, in order to gain a more holistic insight 206	
into the metabolic regulation of health and disease [16]. This has been in a large part 207	
driven by the rapid evolution of new mass spectrometry technologies, in particular 208	
the introduction of high resolution mass spectrometers (HRMS) such as Fourier 209	
Transform-MS and Orbitrap MS, which can provide isotopic resolution as high as 210	
500,000 for some instrumentation. This increase in resolution when combined with 211	
liquid chromatography (i.e. LC-HRMS) has provided capabilities for measuring low 212	
levels of 2H enrichment (comparable to that of traditional “gold standard” GC-IRMS 213	
techniques) of free fatty acids in a high throughput manner, alongside the 214	
measurement of associated whole lipid/lipoprotein species (in the form of 215	
lipidomics/proteomics). This has provided a unique analytical platform capable of 216	
determining how changes in lipid flux interact to influence the whole 217	
lipidome/lipoproteome, hence providing exquisite insight the regulation and control of 218	
lipid metabolism and its interaction with other aspects of metabolism under health 219	
and disease in vivo using D2O. For example, incorporating traditional lipidomics with 220	
D2O permitted the measurement of dynamic changes in lipid profiles associated with 221	
dietary manipulation in animal models. Moreover the simultaneous incorporation of 222	
D2O into high density lipoproteins, alongside cholesterol allows the measurement of 223	
the kinetics of HDL in vivo, an important technique which could greatly benefit the 224	
development of HDL targeted therapies in conditions such as dyslipidemia and 225	
atherosclerosis. Indeed, this has been the target in recent years with a number of 226	
recent studies utilizing these D2O techniques to provide a greater insight into the 227	
mechanisms and efficiency of a number of LDL-cholesterol lowering therapies in 228	
particular. For example, D2O techniques have help to identify that the cholesterol 229	
ester transfer protein (CETP) inhibitor anacetrapib was effective in promoting preβ 230	
HDL formation potentially helping to lower LDL-cholesterol levels, acting as a 231	
beneficial treatment for coronary heart disease. In addition, the administration of the 232	
cholesterol lowering drug ezetimibe was shown to increase the flux of plasma-233	
Formatted: Subscript
Formatted: Subscript
Formatted: Subscript
Formatted: Subscript
Formatted: Subscript
derived cholesterol into fecal neutral sterols and hence increased excretion of 234	
cholesterol from the body, thereby helping to reduce LDL-cholesterol formation and 235	
hence atherosclerosis. These studies highlight the added insight the inclusion of D2O 236	
to lipidomics can provide, and how these techniques will continue to benefit medical 237	
and pharmaceutical insight in future when combined alongside standard biochemical 238	
techniques and novel high throughput OMICs platforms; this is clearly where the 239	
future lies for this niche technique. 240	
	241	
Recent progress in the use of D2O in the study of nucleotide turnover 242	
 243	
There are many scenarios whereby the ability to quantify DNA and RNA turnover is 244	
desirable (e.g. tumourogenesis, skeletal muscle satellite cells, ribosomal biogenesis 245	
etc.). Yet to date, advances in the dynamic measurement of nucleotide metabolism 246	
have considerably lagged behind that of proteins and lipids due to the lack of suitable 247	
precursor compounds. Bromodeoxyuridine and tritiated (radio-active) thymidine have 248	
been utilized, although they are incorporated via salvage pathways that are variable 249	
and affected by extracellular nucleoside concentrations. Moreover, these analogues 250	
are toxic and cannot be used in humans. The potential use of D2O overcomes many 251	
of these restrictions by labeling nucleosides via de novo synthesis - a pathway (figure 252	
1) that is up regulated during cellular division, is unaffected by extracellular 253	
nucleoside concentrations and rarely relies on reutilization. As such methods that are 254	
safe for human use and measure cellular division are available [19]. 255	
 256	
Initial measures of cellular proliferation using D2O in humans were that of fast 257	
turnover blood cells such as PBMC’s. Outside of this, these techniques have been 258	
used over extended periods (4-6 weeks) to quantify DNA synthesis in skeletal 259	
muscle in response to nutritional and exercise interventions [2,20]. This is an area of 260	
specific current interest since controversy still exists to the role of skeletal muscle 261	
stem cells (satellite cells) e.g. in sarcopenia  and exercise adaptation [21,22]. With 262	
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many disorders originating form altered cellular proliferation, these techniques have 263	
also been used to investigate i) B and T cell kinetics in patients with leukemia or HIV 264	
ii) breast epithelial cells in both normal and tumor tissues and, iii) in cellular areas 265	
defined as benign or cancerous from prostate tissue - all showing altered rates of 266	
proliferation. These methods have again therefore shown great potential for 267	
application in a clinical setting. Most recently, D2O was used to measure B cell 268	
proliferation in patients with chronic lymphocytic leukemia (CLL). Deuterium was first 269	
incorporated into CLL cells before treatment with the Bruton’s tyrosine kinase 270	
inhibitor ibrutinib. By monitoring CLL DNA enrichment over the following weeks, it 271	
was demonstrated that ibrutinib dramatically decreases CLL cell birth via the lack of 272	
deuterium label dilution and hence proliferation of new cells [23]. 273	
 274	
In addition to circulating cells, DNA synthesis rates have recently been made from 275	
tissue biopsies of fat, in attempts to link fat metabolism with obesity and insulin 276	
resistance. Storage of excess fat involves adipocyte hypertrophy along with 277	
preadiopacyte and adipocyte proliferation, with fat distribution and storage related to 278	
obesity related diseases. To investigate this, pure adipocytes and preadipocytes 279	
were isolated after D2O labeling, identifying abdominal and femoral fat depots have 280	
different proliferation kinetics [24]. Furthermore the rate of adipocyte replacement 281	
rates positively correlated with BMI and visceral adiposity but negatively correlated 282	
with insulin sensitivity – all signs of impaired metabolic health [25].  283	
 284	
Measures of RNA synthesis are also possible with D2O and have the potential to 285	
inform on dynamic ribosomal biogenesis- a primary determinant of protein synthesis 286	
rates during growth, cellular proliferation and homeostasis. Deoxynucleotides are 287	
reduced from nucleotides and as such opportunities arise for the measurement of 288	
RNA synthesis using D2O; generally abiding by the same principles as above. 289	
Measurements of RNA synthesis in rodent liver have recently been made using D2O 290	
[26]; however currently there is a lack of routine methods in the measurement of 291	
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human RNA synthesis, particularly that in slow turnover tissues i.e. muscle. The 292	
development of such methods will have considerable impact in the clinical field, 293	
especially due to the loss of cell cycle control in many conditions such as cancer [27]. 294	
 295	
 296	
 297	
Conclusion 298	
 299	
D2O applications hold considerable promise to generate unheralded insight into 300	
dynamic metabolism in ‘free living’ and clinical environments. With development of 301	
high-resolution mass spectrometry enabling “D2O-MICS” (protein/lipids/metabolites) 302	
a single bolus of D2O coupled to a tissue biopsy can reveal a more holistic picture of 303	
in vivo metabolic phenotypes and mechanisms of interventions than has ever been 304	
possible in a clinical (i.e. studies in humans) context. Crucially, D2O-MICS can also 305	
give rise to ‘translationally relevant’ predictive, diagnostic and therapeutic biomarkers 306	
in humans, reflecting disease progression and responses to therapeutic 307	
interventions. 308	
 309	
Key Points 310	
 311	
- Having methods that reveal the dynamic turnover of metabolic substrates are 312	
of great importance in unraveling diseases processes and in the future of 313	
personalized medicine. 314	
   315	
- D2O has shown effectiveness at providing longer-term, integrated, 316	
multisubstrate measures (proteins, lipids, nucleic acids) across a range of 317	
tissues and populations. 318	
 319	
- The ease of application and opportunities created to measure a range of 320	
substrates combined with the development of OMIC’s methodologies, D2O 321	
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has great potential to provide a more holistic picture of in vivo metabolic in 322	
clinical populations. 323	
 324	
 325	
 326	
 327	
 328	
 329	
 330	
 331	
 332	
 333	
 334	
 335	
 336	
 337	
 338	
 339	
 340	
 341	
 342	
 343	
 344	
 345	
 346	
 347	
 348	
 349	
Figure Legend 350	
Figure 1 351	
D2O – A multivalent tracer.  D2O can be simply administered by oral consumption 352	
and becomes rapidly equilibrated within body water. Subsequently, deuterium 353	
becomes predictably incorporated into many precursors in which their metabolic fate 354	
can be followed. 355	
 356	
Table Legend 357	
Table 1 –D2O loading regimes. Table 1 shows the dose of D2O and the analytical 358	
machinery required to ensure detection of desired substrates. The doses are taken 359	
from published examples or experimental calculations and can inform on the 360	
necessary D2O administration depending on the mass spectrometry instrumentation 361	
available. (*) Turnover rates of individual proteins and lipids vary and so earlier 362	
sampling is preferable to capture maximum number of analytes. AP, atom percent. 363	
LOD, limit of detection. GC-MS, gas chromatography mass spectrometry. GC-pyr-364	
IRMS, gas chromatography pyrolysis isotope ratio mass spectrometry. LC-HRMS, 365	
liquid chromatography high resolution mass spectrometry.  366	
 367	
 368	
 369	
 370	
 371	
 372	
 373	
 374	
 375	
 376	
 377	
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Application Dose of D2O (70AP) 
Measurement 
Duration 
Minimal Analytical 
Requirement LOD 
Protein turnover 
Acute  400ml 3hrs  GC-pyr-IRMS 0.0005% 
Chronic 150ml + 50ml/wk 150ml + 100-150ml/d 
2d – 6wk  
4wk– 6wk 
GC-pyr-IRMS 
GC-MS 
0.0005% 
0.5% 
Individual* 150-400ml + 80-100ml/d 1d-4wk  LC-HRMS 0.0005% 
Lipid turnover 
Acute 150ml + 50ml/wk 2d – 6wk LC-HRMS 0.0005% 
Chronic 150-400ml + 100-150ml/d 4wk-10wk  GC-MS 0.5% 
Individual* ~300ml 1d- 6wk  LC-HRMS 0.0005% 
Nucleic acid turnover 
DNA/RNA fast (>5%.d) 
 
 
150 ml + 50ml/wk 
150ml + 100-150ml/d 
1d – 6wk 
2d – 6wk  
GC-pyr-IRMS 
GC-MS 
0.0005% 
0.5% 
DNA/RNA Slow (<5%.d) 
 
150 ml + 50ml/wk 
150ml + 100-150ml/d 
1d – 6wk 
4wk – 6wk  
GC-pyr-IRMS 
GC-MS 
0.0005% 
0.5% 
Deleted: % 
Oral	
Consumption
H2O D2O
Protein	Synthesis	
Fat	Synthesis	
RNA	+	DNA	Synthesis
Proteomics
Fluxomics
Metabolomics
Protein	1 Protein	2
2	%.d-1 5	%.d-1
